EMEA-000060-PIP07-19

Key facts

Invented name
Ilaris
Active substance
Canakinumab
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0366/2019
PIP number
EMEA-000060-PIP07-19
Pharmaceutical form(s)
  • Powder for solution for injection
  • Solution for injection
Condition(s) / indication(s)
Treatment of gout
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
W: decision granting a waiver in all age groups for all conditions or indications

Decision

Related content

How useful was this page?

Add your rating